Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DYNACIRC vs AFEDITAB CR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dynacirc (isradipine) is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance, thereby lowering blood pressure.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Hypertension
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
2.5-10 mg orally once daily; titrate based on response. Maximum 20 mg/day.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
Terminal elimination half-life is 7-8 hours. In elderly patients or those with hepatic impairment, half-life may be prolonged up to 14 hours, necessitating dose adjustment.
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Primarily hepatic via CYP3A4 isoenzyme; undergoes extensive first-pass metabolism.
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Primarily hepatic metabolism (CYP3A4) with <1% excreted unchanged in urine; approximately 60% of metabolites are excreted in feces via bile, and 35% in urine.
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
Approximately 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
92-98% bound to plasma proteins (primarily albumin)
Volume of distribution is 3-5 L/kg, indicating extensive tissue distribution beyond the vascular compartment.
0.5-0.9 L/kg; high distribution indicates extensive tissue binding
Oral bioavailability is approximately 30-40% due to extensive first-pass metabolism by CYP3A4 in the liver and gut wall.
Oral extended-release: approximately 50-60% due to first-pass metabolism; absolute bioavailability is 45-60%
Cr Cl <30 m L/min: 2.5 mg once daily; increase cautiously. Cr Cl ≥30 m L/min: no adjustment needed.
No adjustment required for any degree of renal impairment, but use with caution in patients with severe renal failure due to risk of hypotension.
Child-Pugh A: use with caution, start at 2.5 mg daily. Child-Pugh B or C: not recommended due to extensive hepatic metabolism.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Safety and efficacy not established; no standard pediatric dosing.
Not recommended for use in pediatric patients; safety and efficacy not established.
Initiate at 2.5 mg once daily; increase slowly due to increased systemic exposure and risk of hypotension.
Initiate at lower end of dosing range (30 mg once daily) due to increased sensitivity to hypotensive effects and potential for reduced hepatic clearance.
None
No FDA black box warning.
Use with caution in patients with heart failure, aortic stenosis, or severe left ventricular dysfunction.,May cause hypotension, especially with concurrent beta-blocker use.,Avoid abrupt withdrawal; taper gradually.,Monitor for peripheral edema, particularly in the lower extremities.
Hypotension, especially with immediate-release formulations,Peripheral edema,Hepatic impairment,Increased angina/acute MI upon withdrawal or dose escalation,Beta-blocker withdrawal,Congestive heart failure
Hypersensitivity to isradipine or any of its components.,Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) is contraindicated.
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concomitant use with strong CYP3A4 inducers (e.g., rifampin),Kock pouch (ileostomy)
Grapefruit juice increases isradipine bioavailability; avoid concurrent use. No other significant food interactions. Maintain consistent salt intake to avoid blood pressure fluctuations.
Grapefruit juice increases nifedipine levels via CYP3A4 inhibition; avoid consumption. High-fat meals may delay absorption but do not alter overall exposure. Avoid alcohol as it can exacerbate vasodilation and hypotension.
First trimester: No adequate studies; animal reproduction studies not available. Second trimester: Possible fetal bradycardia, hypotension, hypoxia if used after 20 weeks due to calcium channel blocker effects. Third trimester: Increased risk of fetal hypoxia, oligohydramnios, and neonatal complications. Avoid use in pregnancy unless benefit outweighs risk.
Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine growth restriction (IUGR), and oligohydramnios; may cause neonatal hypotension, bradycardia, and hypoglycemia if used near term. Contraindicated in pregnancy for hypertension; use only if benefit outweighs risk (e.g., tocolysis).
Excretion in human milk unknown; M/P ratio not determined. Risk of hypotension in neonate. Use with caution, monitor infant for signs of hypotension.
Nifedipine excreted into breast milk; M/P ratio approximately 0.42-0.77; limited human data; no adverse effects reported in infants; use with caution during breastfeeding.
No specific dose adjustments established; pharmacokinetics may be altered due to increased plasma volume, but no studies. Use lowest effective dose and monitor for hypotension.
Plasma clearance may increase due to higher volume of distribution and metabolism; no specific dose adjustment recommended; titrate based on maternal blood pressure and response; avoid around labor due to tocolytic effect.
Dynacirc (isradipine) is a dihydropyridine calcium channel blocker used for hypertension. It has high vascular selectivity and minimal negative inotropic effects. Avoid use in patients with advanced aortic stenosis. Dose adjustment may be needed in elderly or hepatic impairment. Can cause gingival hyperplasia; maintain good oral hygiene.
AFEDITAB CR is a controlled-release formulation of nifedipine, a dihydropyridine calcium channel blocker. Avoid grapefruit juice as it inhibits CYP3A4 metabolism, increasing nifedipine levels. Use cautiously in patients with aortic stenosis or left ventricular dysfunction due to risk of hypotension. Do not crush or chew tablets; intact shell may appear in stool.
Take exactly as prescribed, usually twice daily.,Do not stop suddenly without consulting your doctor.,May cause dizziness or lightheadedness; avoid driving if affected.,Report any swelling of gums, ankles, or feet.,Avoid grapefruit juice as it can increase drug levels.
Swallow the tablet whole; do not crush, chew, or break it.,Avoid grapefruit juice while taking this medication.,Do not discontinue abruptly; taper under medical supervision.,Report symptoms of hypotension like dizziness or fainting.,Limit alcohol intake as it may worsen side effects.,Monitor for fluid retention (ankle swelling) and notify doctor if worsening.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DYNACIRC vs AFEDITAB CR, answered by our medical review team.
DYNACIRC is a Calcium Channel Blocker that works by Dynacirc (isradipine) is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance, thereby lowering blood pressure.. AFEDITAB CR is a Calcium Channel Blocker that works by Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DYNACIRC and AFEDITAB CR depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DYNACIRC is: 2.5-10 mg orally once daily; titrate based on response. Maximum 20 mg/day.. The standard adult dose of AFEDITAB CR is: 30-60 mg orally once daily, extended-release; maximum 90 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DYNACIRC and AFEDITAB CR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DYNACIRC is classified as Category C. First trimester: No adequate studies; animal reproduction studies not available. Second trimester: Possible fetal bradycardia, hypotension, hypoxia if used after 20 weeks due to ca. AFEDITAB CR is classified as Category C. Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine gro. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.